Ready-to-use pefloxacin infusion for surgical prophylaxis
Bapat, R.D.; Mohite, J.D.; Bowalekar, S.K.; Raghu, C.N.
Advances in Therapy 11(5): 269-275
1994
ISSN/ISBN: 0741-238X PMID: 10150267 Document Number: 423209
The efficacy of pefloxacin in preventing postsurgical infection was demonstrated in an open, comparative, randomized clinical trial. The 120 evaluable patients were divided into four groups of 30 each. Group A served as controls. Groups B, C and D received one, two, and six doses, respectively, of pefloxacin 400 mg in 100-mL solution as an intravenous infusion. The majority of treated patients benefitted from pefloxacin therapy, with only 3% to 7% developing infection. In contrast, 20% of the placebo group developed infection within 5 days after surgery. Two of the 90 treated patients experienced mild side effects. One to six doses of ready-to-use pefloxacin infusion may be administered safely to provide antibacterial coverage during surgery.